Gavin Stuart

12.1k total citations · 2 hit papers
118 papers, 6.1k citations indexed

About

Gavin Stuart is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Epidemiology. According to data from OpenAlex, Gavin Stuart has authored 118 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Reproductive Medicine, 49 papers in Obstetrics and Gynecology and 45 papers in Epidemiology. Recurrent topics in Gavin Stuart's work include Ovarian cancer diagnosis and treatment (54 papers), Endometrial and Cervical Cancer Treatments (47 papers) and Cervical Cancer and HPV Research (44 papers). Gavin Stuart is often cited by papers focused on Ovarian cancer diagnosis and treatment (54 papers), Endometrial and Cervical Cancer Treatments (47 papers) and Cervical Cancer and HPV Research (44 papers). Gavin Stuart collaborates with scholars based in Canada, United States and United Kingdom. Gavin Stuart's co-authors include Ignace Vergote, Jill Nation, Ángel J. Lacave, Tom Ehlen, Gunnar B. Kristensen, Corneel Coens, Antonio Casado, N.S. Reed, René H.M. Verheijen and Nick Johnson and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Gavin Stuart

116 papers receiving 5.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

2010 1.7k citations Ignace Vergote, Gunnar B. Kristensen et al. profile →
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

2006 540 citations Ignace Vergote, Gavin Stuart et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Gavin Stuart	3.7k	2.6k	2.1k	1.6k	1.1k	118	6.1k
S. Pecorelli	3.5k 0.9×	1.8k 0.7×	3.5k 1.6×	1.3k 0.8×	1.2k 1.1×	97	6.8k
Sean Kehoe	3.0k 0.8×	1.9k 0.7×	2.4k 1.1×	1.4k 0.9×	900 0.9×	146	5.8k
Roberto Angioli	2.8k 0.8×	2.3k 0.9×	3.0k 1.4×	1.1k 0.7×	747 0.7×	286	6.3k
Amanda N. Fader	3.0k 0.8×	2.3k 0.9×	4.2k 2.0×	1.6k 1.0×	723 0.7×	222	7.3k
Ludovico Muzii	4.2k 1.1×	2.4k 0.9×	3.9k 1.8×	981 0.6×	818 0.8×	352	7.9k
A. Peter M. Heintz	2.2k 0.6×	2.4k 0.9×	2.1k 1.0×	987 0.6×	1.1k 1.0×	140	6.0k
J. Taylor Wharton	2.7k 0.7×	2.5k 1.0×	2.9k 1.4×	2.0k 1.3×	1.5k 1.4×	166	7.5k
Larry J. Copeland	4.5k 1.2×	3.0k 1.1×	2.7k 1.3×	2.0k 1.3×	632 0.6×	210	7.7k
Linda F. Carson	2.3k 0.6×	1.6k 0.6×	1.5k 0.7×	1.4k 0.9×	596 0.6×	122	5.4k
Charles Levenback	2.6k 0.7×	2.6k 1.0×	4.5k 2.1×	1.5k 0.9×	2.0k 1.9×	102	6.9k

Countries citing papers authored by Gavin Stuart

Since Specialization

Citations

This map shows the geographic impact of Gavin Stuart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gavin Stuart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gavin Stuart more than expected).

Fields of papers citing papers by Gavin Stuart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gavin Stuart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gavin Stuart. The network helps show where Gavin Stuart may publish in the future.

Co-authorship network of co-authors of Gavin Stuart

This figure shows the co-authorship network connecting the top 25 collaborators of Gavin Stuart. A scholar is included among the top collaborators of Gavin Stuart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gavin Stuart. Gavin Stuart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gottschlich, Anna, Quan Hong, Lovedeep Gondara, et al.. (2024). Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study. Cancer Epidemiology Biomarkers & Prevention. 33(7). 904–911. 1 indexed citations

Gottschlich, Anna, Lovedeep Gondara, Laurie Smith, et al.. (2023). Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study. The Lancet Regional Health - Americas. 26. 100598–100598. 3 indexed citations

Smith, Laurie, Lindsay Hedden, Andrew J. Coldman, et al.. (2021). Cost‐effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial. Cancer Medicine. 10(9). 2996–3003. 14 indexed citations

Gottschlich, Anna, Dirk van Niekerk, Laurie Smith, et al.. (2020). Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort. Cancer Epidemiology Biomarkers & Prevention. 30(1). 22–29. 16 indexed citations

Coldman, Andrew J., Dirk van Niekerk, Mel Krajden, et al.. (2019). Disease detection at the 48‐month exit round of the HPV FOCAL cervical cancer screening trial in women per‐protocol eligible for routine screening. International Journal of Cancer. 146(7). 1810–1818. 2 indexed citations

Vergote, Ignace, Corneel Coens, Matthew Nankivell, et al.. (2019). Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials. Obstetrical & Gynecological Survey. 74(3). 156–158. 30 indexed citations

Ogilvie, Gina, Dirk van Niekerk, Mel Krajden, et al.. (2018). Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. Obstetrical & Gynecological Survey. 73(11). 632–634. 32 indexed citations

Bookman, Michael A., Aikou Okamoto, Gavin Stuart, et al.. (2017). Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. Annals of Oncology. 28(suppl_8). viii30–viii35. 29 indexed citations

Stuart, Gavin, Henry C Kitchener, Jan B. Vermorken, et al.. (2017). The Impact of an International Network (Gynecologic Cancer InterGroup) for Clinical Research on Global Capacity for Gynecologic Cancer Clinical Trials. International Journal of Gynecological Cancer. 27(4). 813–818. 1 indexed citations

10.

Stuart, Gavin. (2008). Future opportunities of the Gynecological Cancer Intergroup. International Journal of Gynecological Cancer. 18. 71–73. 1 indexed citations

11.

Stuart, Gavin, Gregory Taylor, Christina Bancej, et al.. (2004). Report of the 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control. Journal of Obstetrics and Gynaecology Canada. 26(11). 1004–1014. 16 indexed citations

12.

Vergote, Ignace, et al.. (2002). First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel-epirubicin-carboplatin (TEC) vs paclitaxel-carboplatin (TC). Interim results of an NSGO-EORTC GCG - NCIC CTG intergroup Phase III study. International Journal of Gynecological Cancer. 12(5). 4 indexed citations

13.

Piccart, Martine, K. Bertelsen, Gavin Stuart, et al.. (2002). Long-term follow-up confirms a survival advantage of paclitaxel-cisplatin (CP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer. Annals of Oncology. 5 indexed citations

14.

Piccart, Martine, Gavin Stuart, Jim Cassidy, et al.. (1999). Intergroup collaboration in ovarian cancer: a giant step forward. Annals of Oncology. 10. S83–S86. 13 indexed citations

15.

Stuart, Gavin, et al.. (1999). . Annals of Oncology. 10(1). 83–86. 2 indexed citations

16.

Stuart, Gavin, S. Elizabeth McGregor, Máire A. Duggan, & Jill Nation. (1997). Review of the screening history of Alberta women with invasive cervical cancer.. PubMed. 157(5). 513–9. 49 indexed citations

17.

Anderson, G. Harvey, et al.. (1996). Cervical cancer screening: are the 1989 recommendations still valid? National Workshop on Screening for Cancer of the Cervix.. PubMed. 154(12). 1847–53. 20 indexed citations

18.

Duggan, Máire A., et al.. (1995). Uterine Atypical Polypoid Adenomyoma and Ovarian Endometrioid Carcinoma. International Journal of Gynecological Pathology. 14(1). 81–86. 8 indexed citations

19.

Jarrell, John, et al.. (1992). Regulation of total ovarian glutathione content in the rat. Reproductive Toxicology. 6(2). 133–135. 5 indexed citations

20.

Stuart, Gavin, et al.. (1988). Laser vaporization of vaginal intraepithelial neoplasia. American Journal of Obstetrics and Gynecology. 158(2). 240–243. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact